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Alteration of specific cytokine 
expression patterns in patients with 
breast cancer
Kosuke Kawaguchi1, Masashi Sakurai2, Yasuko Yamamoto3, eiji suzuki1, Moe tsuda1, 
Tatsuki R. Kataoka4, Masahiro Hirata4, Mariko Nishie1, Takashi Nojiri5, Motofumi Kumazoe6, 
Kuniaki saito2,3 & Masakazu toi1
Systemic inflammation has been associated with aggressive tumor growth, invasion, and metastasis. 
Here we performed a comprehensive analysis of 26 kinds of inflammatory cytokine expression patterns 
among 185 patients with breast cancer and 54 healthy volunteers followed by chemometric analysis. 
We identified the specific cytokine expression patterns of breast cancer patients compared to healthy 
volunteers with (1) VEGF, IL-9, GM-CSF, IL-13, IL-4, and IFNγ, (2) IL-8, IL-10, IL-12, IL-5, IL-7, IL-1α, 
GCSF, IL-1β, and TNFα and (3) IL-2, Eotaxin, MIP1β, MIP1α, IL-17, and bFGF. Among the patients with 
breast cancer, we identified the specific cytokine signature of metastatic patients compared to non-
metastatic patients. We also established a mathematical model for distinguishing patients with breast 
cancer from healthy volunteers and metastatic patients from non-metastatic patients. This cytokine 
network analysis could provide new insights into early intervention and effective therapeutic strategy 
for patients with breast cancer.
Inflammation plays a crucial role in the immune system and defense against several pathogens, including viruses 
and bacteria, and has been proposed to mediate the initiation and promotion of tumors, angiogenesis and metas-
tasis1. Inflammatory cells are attracted by oncogenic changes, hypoxia, cytokines, and chemokines, among other 
factors. Inflammation of a tumor microenvironment comprises infiltrating immune cells and activated fibro-
blasts, which secrete cytokines, chemokines, and growth factors to which the tumor responds2. Moreover, a recent 
study has shown that inflammation signaling, especially involving IL-6/JAK2/Stat3, plays a crucial role in the 
stem cell-like characteristics of breast cancer (BC)3.
Measurement of cytokines in serum involves well-established methods in clinical practice. IL-6 may stimu-
late cancer cell growth and contribute to recurrence and metastasis in BC4, with GCSF, IL-6, and IL-17 able to 
distinguish between BC and no-cancer groups5. While most studies have found elevated levels of cytokines in 
patients with BC, a study of 90 patients with BC and 15 healthy volunteers based on univariate analysis found no 
differences in baseline cytokine levels between the cancer patients and the healthy volunteers, as evidenced by 
plasma levels of IL-1β, IL-6, IL-8, IL-10, IL-12 and TNF-α6. However, the direct correlation between inflamma-
tory cytokine levels and clinical outcomes has not been evident in patients with BC.
Chemometrics-driven evaluations, especially principal component analysis (PCA), are among the data anal-
ysis methods used for statistical inference of low-dimensional parameters with high-dimensional data7; further-
more, many valuable diagnostic data have been revealed by PCA, in particular, in comprehensive gene analysis8. 
Recently, we reported that mRNA expressions of PD-L1, FOXP3, CD80, CD40 and CD14 in peripheral blood 
mononuclear cells are affected by disease development and progression9. These data revealed that circulating 
immune cells were affected by BC development and progression.
Here we performed a comprehensive analysis of inflammatory cytokine in serum derived from 185 patients 
with BC and 54 healthy volunteers. Our study showed the patients with BC had three different cytokine 
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expression patterns: (1) VEGF, IL-9, GM-CSF, IL-13, IL-4, and IFNγ; (2) IL-8, IL-10, IL-12, IL-5, IL-7, IL-1α, 
GCSF, IL-1β, and TNFα; (3) IL-2, eotaxin, MIP1β, MIP1α, IL-17, and bFGF. Our data showed that BC patients 
were distinguishable from healthy volunteers. In the patients with BC, metastatic human epidermal growth factor 
receptor (HER2)-positive BC patients and triple-negative BC (TNBC) patients showed the specific signature 
plotting pattern. Furthermore, these cytokine profiles correlated with clinical outcomes in BC.
Results
Patient characteristics. Data on 185 BC patients and 54 women healthy volunteers were available. All of 
the samples were collected at the time of diagnosis. One-quarter of patients had metastatic BC. Among the BC 
patients, 62.2% were estrogen receptor-positive and HER2-negative with luminal-type BC, 24.3% had HER2-type 
BC, and 13.5% had TNBC. Details of patient characteristics are provided in Table 1.
Expression pattern of cytokines in BC patients was distinct from healthy volunteers. PCA of 
185 BC patients and 54 healthy volunteers showed that the former were clearly distinguishable from the latter 
(Fig. 1a). Almost all healthy volunteers were located in Area 1; there was only one healthy volunteer in Area 4. 
In contrast, BC patients were located in broader zones. A small overlap area between healthy volunteers and BC 
patients can be observed. Figure 1b shows the contribution of each cytokine to Primary Component 1 (PC1) and 
PC2. Cytokines, which existed in Area 2 (see Fig. 1b), contributed to Areas 1 and 2 (see Fig. 1a), such as in the 
form of IFN-γ and IL-13, and also existed in Area 4 (see Fig. 1b) and contributed to Areas 2 and 4 (see Fig. 1a), 
such as in the form of IL-17 and bFGF.
Expression pattern of cytokines in cancer progression and phenotypes. Next, we investigated the 
expression pattern in BC patients by subgroup plotting. Figure 2a depicts the PCA of the plot according to tumor 
staging. The patients with Stages 1, 2 and 3 (non-metastatic patients) were primarily located in Areas 3 and 4. In 
contrast, the patients with Stage 4 were primarily located in Areas 1 and 2. Figure 2b depicts the PCA of the plot 
of the BC phenotype. There was no signature for the luminal type, whereas the HER2 type tended to exist in the 
upper area (Areas 1 and 2) and the TNBC type tended to exist in the lower area (Areas 3 and 4). There was no 
significant pattern analyzed according to Ki67 and tumor grade (Fig. 2c,d).
Correlation mapping of cytokines in BC patients and healthy volunteers. Next, we investigated 













ER-positive and/or PR-positive 144 (77.8%)
ER-negative and PR-negative 41 (22.2%)
HER2 status
HER2 positive 45 (24.3%)













Table 1. Characteristics of patients with breast cancer in the study.
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strong correlation combinations of cytokines. Figure 3c shows the heat map of the cytokines’ network with clus-
ter analysis in BC patients. In BC patients, there were three clusters: (1) VEGF, IL-9, GM-CSF, IL-13, IL-4, and 
IFNγ; (2) IL-8, IL-10, IL-12, IL-5, IL-7, IL-1α, GCSF, IL-1β, and TNFα; (3) IL-2, eotaxin, MIP1β, MIP1α, IL-17, 
and bFGF. These results indicate that there were specific correlation patterns in BC patients. We also checked the 
correlation between these cytokines and TGFβ, which has been established as essential for cancer progression, 
because of its prominent role in the regulation of cell growth, differentiation and migration10. Moreover, there was 
no significant correlation with another 26 cytokines (Supplementary Fig. S1).
Prediction of BC prognosis and therapeutic effect by PCA and IL-17 expression pattern. We 
investigated the correlation between PCA expression patterns and BC prognosis. We followed up Stage 1–3 
patients, with distant metastasis occurring in 14 out of 139 patients (Fig. 4a). Interestingly, these metastatic 
patients have distributed in the PC1 < 0 areas. Kaplan Mayer analysis showed that disease-free survival (DFS) 
was significantly shorter in patients in PC1 < 0 (Areas 2 and 4) compared to PC1 > 0 (Areas 1 and 3) (hazard 
ratio: 0.21; 95% confidence interval [CI], 0.075 to 0.681; P = 0.009 with the use of the log-rank test) (Fig. 4b). 
Figure 1. PCA score plot and corresponding loading plot for subjects. PCA score plot (a) and corresponding 
loading plot (b) of measured serum cytokines for healthy volunteers (blue) and BC patients (red). Area 1: 
PC1 > 0, PC2 < 0, Area 2: PC1 < 0, PC2 < 0, Area 3: PC1 > 0, PC2 > 0, Area 4: PC1 < 0, PC2 > 0.
4Scientific RepoRts |          (2019) 9:2924  | https://doi.org/10.1038/s41598-019-39476-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
In subgroup analysis, the only grade was involved in DFS. Higher stage and HER2 and TNBC subtypes had 
also trend, but there was not significant due to small sample size (Supplementary Fig. S2). We also investigated 
the correlation between IL-17 and BC prognosis due to IL-17 being the strongest effector about PC1. There was 
significantly poor prognosis in the high IL-17 group, which was defined by median levels of IL-17 (hazard ratio: 
0.23; 95% CI, 0.078 to 0.662; P = 0.006 with the use of the log-rank test) (Fig. 4c). Next, we investigated the cor-
relation between PCA and IL-17 expression patterns and therapeutic effects among BC patients who received 
neoadjuvant chemotherapy (Tables 2 and 3). A pathological complete response (pCR) was achieved in 36.6% of 
all cases (30/82), 25.0% of PC1 < 0 cases (11/44), 50.0% of PC1 > 0 cases (19/38) (Fig. 4d), 24.4% of high IL-17 
cases (10/41) and 48.8% of low IL-17 cases (20/41) (Fig. 4e). We checked alteration between cytokine profile at 
BC diagnosis and after neoadjuvant therapy using eight patient’s samples (Supplementary Fig. S3). Our findings 
indicate that there were significant alteration patterns in non-pCR with recurrence case. These results suggest that 
PCA based on serum cytokine levels could predict BC prognosis and therapeutic effects.
Modeling of orthogonal projections to latent structures (OPLS) based on cytokine array pro-
vides information on patients with BC. Our data based on PCA and correlation analysis suggested the 
existence of three different types of cytokine patterns in the patients with BC. Based on the cytokine pattern, we 
performed OPLS-discriminant analysis (OPLS-DA) to predict the patients’ status and classification. In this anal-
ysis, healthy volunteers, patients with BC, operable patients with BC (Stages 1–3), metastatic patients with BC 
(Stage 4), TNBC and other types (luminal and HER2) are used as classification variants.
As shown in Fig. 5a–c, we showed the scatterplot for each variant according to the trained model based on 
all sample data. The red and blue plot indicates each sample and the ellipse line represents the variance in each 
category. Intuitively, the smaller overlapped area of variance ellipses indicates the more precise prediction of 
classification. Our data show that the OPLS-DA model could distinguish BC patients from healthy volunteers 
Figure 2. Correlation between PCA score and BC characteristics. PCA score plot with BC characteristics. (a) 
cancer stage, (b) cancer subtype, (c) % expression of Ki67 in the tumor, (d) grade (Elston-Ellis modification of 
Scarff-Bloom-Richardson grading system).
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(Fig. 5a). In the analysis on operable and metastatic BC, even the overlap of variance ellipses is slightly larger 
than in the previous plot, while the data also suggest that our OPLS-DA model may predict both operable and 
metastatic BC (Fig. 5b).
In contrast, in the analysis on TNBC and other types, a large part of each ellipse line overlap, indicating 
that our OPLDS-DA model makes it difficult to distinguish TNBC from other types (Fig. 5c). To validate our 
OPLS-DA models, we performed k-fold cross-validation and predicted classification performance, here we used 
k = 5. The analysis of TNBC and other types could not be performed because of the insufficient sample size. 
Precision was calculated by using the following formula: precision = (true positive)/(true positive + false pos-
itive). The recall was also calculated using the following formula: recall = (true positive)/(true positive + false 
negative). As shown in Fig. 5d, the OPLDS-DA model for predicting BC patients and healthy volunteers shows 
satisfactory precision and recall values.
Moreover, the OPLDS-DA model for predicting both operable and metastatic BC shows potent precision and 
recall values. These results indicate that OPLS-DA analysis based on serum cytokine levels can precisely predict 
Figure 3. Correlation mapping of cytokines in BC patients and healthy volunteers. (a) Individual top 20 high 
correlation coefficient scatterplots. (b) The value of the correlation coefficient and the p-value of the top 20 high 
correlation coefficients. Statistical analysis was performed by the Pearson’s correlation test. (c) Heart map of 
cytokines’ network with cluster analysis in BC patients. Dark blue means high positive correlation and dark red 
mean high negative correlation.
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patients with BC. More importantly, our data showed that OPLS-DA analysis based on serum cytokine levels 
could predict operable or metastatic BC with a 90% probability.
Correlation between serum cytokine expression and immune profile on BC tissues. The previ-
ous study revealed that immune profile, such as tumor infiltrating lymphocytes (TILs) and FOXP3, on BC tissues 
has both predictive and prognostic values in BC11,12. However, the correlation between serum cytokine expression 
Figure 4. Prediction of BC prognosis and therapeutic effect by PCA and IL-17 expression pattern. (a) PCA 
score plots of the patients with Stage 1–3 operable BC. The blue circles plot patients in whom metastatic disease 
occurred, along with the score for PC1 (X-axis) and PC2 (Y-axis). (b,c) Kaplan-Meier estimate of overall 
survival in Stage 1–3 operable BC patients by PC value and IL-17 expression level. B: In the PC1 < 0 areas, 
there was significantly poor prognosis compared to patients who were in the PC1 > 0 area. Hazard ratio: 0.21; 
95% CI, 0.075 to 0.681; P = 0.009 with the use of the log-rank test. (c) There was significantly poor prognosis 
in the high IL-17 group. Hazard ratio: 0.23; 95% CI, 0.078 to 0.662; P = 0.006 with the use of the log-rank test. 
(d,e) Correlation between PCA and IL-17 expression patterns and BC therapeutic effects among patients who 
received neoadjuvant chemotherapy. (d) A pCR was achieved in 36.6% of all cases (30/82), 25.0% of PC1 < 0 
cases (11/44) and 50.0% of PC1 > 0 cases (19/38); p = 0.0231. (e) 24.4% of high IL-17 cases (10/41) and 48.8% of 
low IL-17 cases (20/41); p = 0.0382. Statically analysis was conducted using Fisher’s exact test.
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and immune profile in BC tissues is still unclear. We analyzed this correlation by evaluating TILs and FOXP3 in 
breast cancer tissues to uncover the immune response in breast cancer tumor microenvironment. We evaluate 83 
paired samples in this study and characteristic of patients is in Supplementary Table S1. Interestingly, the majority 
of cytokines have a negative correlation with TILs and have a positive correlation with FOXP3 (Fig. 6a–c). These 
results suggest that high TILs correlates with low pro-inflammatory cytokine expression status and high FOXP3 
correlates with high pro-inflammatory cytokine expression status in BC.
Characteristic
PC1 < 0 PC1 > 0
p-valueNo. % No. %
ALL patients 82 44 38
Age, years 0.929
Median 52.5 53 51.5
Range 27–78
Subtype 0.796
Luminal 29 17 (58.6%) 12 (41.4%)
HER2 33 17 (51.5%) 16 (48.5%)
Triple negative 20 10 (50.0%) 10 (50.0%)
Grade 0.971
2 39 21 (53.8%) 18 (46.2%)
3 43 23 (53.5%) 20 (46.5%)
Ki-67 0.64
Median 30 30 30
Range 10–91.6 10–91.6 10–91.6
Chemotherapy regimen
Anthracycline 45 (54.9%) 23 (51.1%) 22 (48.9%) 0.61
Taxane 79 (96.3%) 42 (53.2%) 37 (46.8%) 0.645
Platinum 27 (32.9%) 12 (44.4%) 15 (55.6%) 0.241
Trastuzumab 32 (39.0%) 16 (50.0%) 16 (50.0%) 0.595
Table 2. Correlation between cytokine expression pattern and clinical features who received neoadjuvant 
chemotherapy (PCA).
Characteristic
IL-17 high IL-17 low
p-valueNo. % No. %
ALL patients 82 41 41
Age, years 0.273
Median 52.5 51 54
Range 27–78 31–73 27–78
Subtype 0.273
Luminal 29 16 (55.2%) 13 (44.8%)
HER2 33 13 (39.4%) 20 (60.6%)
Triple negative 20 12 (60.0%) 8 (40.0%)
Grade 0.015*
2 39 25 (64.1%) 14 (35.9%)
3 43 16 (37.2%) 27 (62.8%)
Ki-67 0.79
Median 30 30 30
Range 10–91.6 10–90 10–91.6
Chemotherapy regimen
Anthracycline 45 (54.9%) 24 (53.3%) 21 (46.7%) 0.292
Taxane 79 (96.3%) 46 (58.2%) 33 (41.8%) 0.771
Platinum 27 (32.9%) 15 (55.6%) 12 (44.4%) 0.701
Trastuzumab 32 (39.0%) 16 (50.0%) 16 (50.0%) 0.209
Table 3. Correlation between cytokine expression pattern and clinical features who received neoadjuvant 
chemotherapy (IL-17).
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Discussion
Tumor tissue is the gold standard for clinical and investigational sequencing. However, major barriers exist 
regarding acquisition and utility, such as inconvenience from a scheduling perspective, the cost of patient care, 
and invasive procedures for patients. The primary limitation of tissue biopsy is heterogeneity, which characterizes 
most advanced cancers13, with heterogeneity existing between metastases within the same patient. To overcome 
the limitations of tissue biopsy, less invasive techniques capable of capturing tumor heterogeneity and the molec-
ular changes that cancer cells undergo when they are exposed to therapy are needed14. The blood test, which is the 
appropriate and most straightforward measure for mass screening, is widely used in the testing of several diseases 
including metabolic syndrome.
In this study, we presented a novel approach of cytokine networks based on the comprehensive analysis of 26 
kinds of expression inflammatory cytokine expression patterns, followed by chemometric analysis. We revealed 
the specific cytokine expression patterns between patients with BC and healthy volunteers and the specific 
cytokine signature in metastatic patients with BC.
Recent studies have suggested the existence of complex crosstalk between the tumor and host, which plays a 
crucial role in tumor initiation, growth, metastasis, and drug resistance. The inflammatory cytokine is the main 
component of this crosstalk. For instance, several inflammatory cytokines are crucial in the pre-metastatic niche 
Figure 5. OPLS modeling based on cytokine array provides information on patients with BC. (a–c) OPLS-DA 
score plots of healthy volunteers and patients with BC, operable BC/metastatic BC, and TNBC/other types. 
The distributions of each sample are plotted by the red and blue circles, along with the score of the predictive 
component (X-axis) and the orthogonal component (Y-axis). The ellipse lines on the plots indicate the variance 
of the samples, which is drawn according to the Mahalanobis distance. (d) Summary of classification results 
(SD) calculated by k-fold cross-varidation (k = 5). Precision and recall refer to the relevance of the classification. 
See the main text for definitions.
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in several animal models. There were several reports, which described cytokines and BC progression. Wang et al. 
reported that serum IL-6, IL-8, IL-10, SCC-Ag, and CYFRA 21-1 may serve as potential markers for predicting 
metastasis and prognosis of BC15. Circulating tumor cells (CTCs), which is increased with BC progression and 
metastasis, involved in cytokine expression in BC. Vilsmaier et al. reported that IL-1α is a candidate marker for 
the release of tumor cells and IL-1β, IL-12, sFlt1 and PlGF appears to be related to CTCs release in patients with 
BC16,17. Another group showed that pro-inflammatory cytokines TNFα, IL-6, CSF-1, and IFNγ correlated with 
disseminated tumor cells in BC18. We demonstrate that cytokine expression pattern correlated with both immune 
profiles on BC tissues (Fig. 6a). Inflammation in a tumor microenvironment comprises infiltrating immune cells 
that secrete cytokines, chemokines, and growth factors to which the tumor responds1,19. Previously, we revealed 
that BC progression alters immune profile in peripheral blood mononuclear cells (PBMCs)9. FOXP3 expression 
in PBMCs is one of the genes correlated with BC progression, and we discovered that FOXP3 in BC tissues also is 
correlated with serum cytokine expression pattern. Overall, our results may uncover significant immune response 
in BC tumor microenvironment.
Consistent with these findings, clinical studies have shown the upregulation of several inflammation cytokines 
including G-CSF, IL-6, and IL-17 in patients with BC5. Meanwhile, recent reports have shown that IL-17-producing 
cells increased in tumor tissues and peripheral blood from different cancer patients20 {Numasaki, 2004 #707. 
In contrast, a blood test to measure IL-17 levels is the more feasible way to evaluate the significance of IL-17 in 
tumor microenvironments, compared with measuring IL-17-producing cells. In non-small-cell lung cancer and 
hepatocellular carcinoma, serum IL-17 levels were correlated with poor prognosis21,22. Here, we are the first to 
show that serum IL-17 is up-regulated in BC patients and that high levels of IL-17 are also correlated with poor 
clinical outcomes.
Recently, preclinical models have shown that IL-17 mediates cancer progress via various mechanisms23–28. 
Coffelt et al. reported that increasing systemic IL-17 levels leads to the up-regulation of G-CSF, which subse-
quently causes neutrophil expansion and alteration of the neutrophil phenotype. Another study reported the 
effects of IL-17 and bFGF on mesenchymal stem cell (MSC) growth and elucidated the signaling pathways 
involved. These results indicated that IL-17 increased the frequency of colony-forming unit fibroblast (CFU-F), 
as well as MSC proliferation in a dose-dependent manner, while bFGF supplementation induced an increase in 
cell proliferation27. Consistent with these findings, our data indicated that the interaction of serum IL-17 levels 
with an increased level of both bFGF and G-CSF are correlated with poor DFS among BC patients. While IL-17- 
and IL-17-producing cells are significantly insensitive towards chemotherapy in experimental settings29, little 
Figure 6. Correlation between serum cytokine expression and immune profile on BC tissues. (a) The value of 
the correlation coefficient between serum cytokine expressions and immune profile on BC tissues. The immune 
profile was evaluated TILs and FOXP3 on FFPE samples. Statistical analysis was performed by the Pearson’s 
correlation test. (b,c) PCA score plots of the patients with Stage 1–3 operable BC. (b) TILs (% stromal area), (c) 
FOXP3 (% TILs).
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is known about the correlation between systemic IL-17 levels and sensitivity towards chemotherapy in clinical 
settings, especially concerning BC. Although there are limitations to our study, given that patient characteristics 
include all subtypes and involve various chemotherapy regimens, our data indicate that systemic IL-17 levels are 
correlated with pathological complete response rates in BC patients. To overcome such limitations, we need to 
further investigate the correlation between serum IL-17 levels and clinical outcomes in larger-volume clinical 
trials.
We acknowledge that this study has several other limitations. Notably, this study is retrospective, meaning 
that it is difficult to evaluate correlations between cytokine diversity and clinical outcome due to treatment and 
phenotype bias. We should validate using individual cohort to enhance our conclusion. To overcome this lim-
itation, we are planning to validate using two ongoing clinical trial data set. The first one is to investigate the 
efficacy and safety of dual-HER2 blockage therapy in HER2-positive breast cancer (Clinical trial information: 
UMIN000007576). The other one is to evaluate the safety, antitumor effect and improved prognosis of Nivolumab 
with radiation therapy in patients with HER-2-negative metastatic breast cancer have bone metastasis that pos-
sible to irradiate (Clinical trial information: UMIN000026046). These clinical trials will cover all phenotypes. 
Additionally, we will investigate not only cytokine expression pattern but also tumor immune microenvironment 
status using CyTOF analysis and RNA-seq analysis of PBMCs. Then, we will confirm the correlation between 
cytokine expression pattern and tumor microenvironment status.
In this study, at least in the evaluations of BC development and progression, our analysis could be poten-
tially relevant as we revealed them by OPLS-DA (Fig. 5). To further strengthen our model, we performed 
k-cross-validation as it is used for the development of biomarker classifiers from high dimensional data set30. 
Interestingly, results of k-fold cross-validation showed high accuracy to distinguish BC from HV and stage IV 
patients from stage I-III patients. Additionally, the standard deviation value is less than 5% both recall and preci-
sion rate. Therefore, we think the risk of over-learning is very low. Considering the application, our data are cru-
cial because our results suggest that serum analysis is a useful approach to provide information, for example, on 
the subtype of cancer, inflammation status and prognosis by a 12.5-µl serum sample. Regarding accessibility, for 
example, in terms of low invasion, established method and low cost, the comprehensive analysis of inflammatory 
cytokines in serum could be useful for monitoring inflammation status in the use of antagonizing/neutralizing 
antibodies to address inflammatory cytokine signaling.
Methods
Serum samples. Serum from healthy volunteers, early-stage BC patients, and metastatic BC patients was 
collected by the Department of Breast Surgery, Kyoto University Hospital, and the Resource Center for Health 
Science, Kyoto, Japan. All the BC patient’s samples were collected at the BC diagnosis between April 2011 and 
March 2015. Eight patients had two-point samples, both at diagnosis and after neoadjuvant therapy. Written 
informed consent was given by all patients before collection. All study protocols were approved by the Ethics 
Committee for Clinical Research, Kyoto University Hospital (Authorization Number G424) and performed 
according to the Declaration of Helsinki and the Ethical Guidelines for Epidemiological Research of the Ministry 
of Education, Culture, Sports, Science, and Technology and the Ministry of Health, Labour, and Welfare of Japan. 
Samples were frozen in liquid nitrogen and stored at −80 °C within 2 hours from sample collection. We checked 
if sample storage period effects on cytokine expression in this study (Supplementary Fig. S4). All of the value of 
correlation coefficient were within 0.2, and there was no significant distribution in the characteristic of patients.
Cytokine and chemokine measurement. The cytokines in serum samples, IL-1β, IL-1γα, IL-2, IL-4, 
IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, granulocyte-macrophage-colony-stimulating 
factor, granulocyte colony-stimulating factor, interferon gamma (IFN-γ), monocyte chemoattractant protein-1, 
macrophage inflammatory protein-1α (MIP-1α), macrophage inflammatory protein-1β (MIP-1β), PDGF-BB, 
RANTES, VEGF, bFGF and TNF-α were measured with a Bio-Plex multiplex assay system (Bio-Rad, Hercules, 
CA) according to the manufacturer’s instructions. This analysis was conducted on 12.5-µl serum sample from 
each patient.
Analysis of the immune profile on BC tissues. The paraffin sections were rehydrated and immersed in 
3% hydrogen peroxide for 10 min to quench endogenous peroxidase activity. Epitope retrieval was performed 
by heating the sections at 95 °C in Target Retrieval Solution (pH 9, S2375; Dako) for 30 min in an electric pres-
sure cooker (SR-P37; Panasonic, Tokyo, Japan). All incubations after the blocking step were performed at room 
temperature. The wash buffer was 0.05 M Tris-buffered saline with 0.05% Tween 20 (pH 7.6). Following blocking 
with 5% normal goat serum (Abcam) in PBS for 10 min, the sections were incubated with anti-FOXP3 antibodies 
(236 A/E7; Abcam) for 1 h.
Histopathologic assessment of the percentage of TILs and FOXP3 was performed on one representative 
immunohistochemical section of a tumor using methods recommended by the International TILs Working 
Group 201418. % TILs was defined as the percentage of lymphocyte area per tumor area in vivo samples. Areas of 
in situ carcinomas, normal lobules, necrosis, hyalinization, and crush artifacts were not included. Histopathologic 
evaluation of TILs was performed by two breast pathologists who scored each case independently in a blind man-
ner. The mean values of both observers were obtained as the final scores for each case.
Statistics and data analysis. Multivariate statistical analysis (PCA and OPLS-DA) was performed in order 
to evaluate the measured cytokine data using R version 3.3.1 (R Foundation for Statistical Computing, 2016) 
and the R ropls package version 1.8.0. PCA can project higher-dimension data into lower-dimensional space in 
order to visualize the distribution of complex data. Typically two-dimension is used as the lower-dimensional 
space. Usually, PCA results are represented by a score plot and a loading plot. In a score plot, samples expressing 
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similar cytokine values are plotted in the near position, while the spatial groups of similar samples are recognized 
as a pattern. In a loading plot, the positions of each point corresponding to the cytokine variables describe the 
correlation with the PCs, such as PC1 and PC2. The loading plot implies which cytokines mainly contribute 
to forming the pattern in the score plot. In our PCA calculation, a few outlier samples, which were more than 
10–100 times larger than the average of the distribution, were omitted because substantial outlier values collapse 
the pattern. OPLS-DA is a potent statistical tool, which provides insights into distinguishing between groups of 
high-dimensional spectral data31. The score axis is the predictive component, which is the variation correlated 
to the factor of interest. The orthogonal score axis is the first component of the uncorrelated variations. A χ2 test 
(two-sided, α = 0.05) was used to compare the populations between groups in the score plot, using SPSS 17.0 
(Chicago, IL, USA).
k-fold-cross-validation: The dataset was randomly partitioned into k = 5 disjoint subsets to be used as a train-
ing and testing sets to validate the Delphi exercise-approved diagnostic criteria. Four subsets were used as the 
training set to build a diagnostic model, and the remaining subset was used as the testing set to test the model. 
This process is repeated five times for each dataset, each round with a different training set and complemen-
tary testing set. Model performance was estimated by calculating precision and recall which definitions were 
described at the results section. The averages and standard deviations over the 5 datasets were calculated.
Data Availability
The datasets generated during and analyzed during the current study are not publicly available due to protecting 
participant confidentiality but are available from the corresponding author on reasonable request.
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